Zurueck zur Suche

Reporte zur Charge U015687

Verknuepft ueber VAERS_ID mit VAERSDATA, Vax und Symptoms

4Reporte angezeigt
0Todesfaelle
0Hospitalisiert
0Lebensbedrohlich
0Bleibende Schaeden
NJ 2 MI 1 WI 1

VAERS 2582895

MERCK & CO. INC. · VARICELLA (VARIVAX) · Charge U015687

mild
Staat
NJ
Alter
25,0
Geschlecht
F
Eingang
16.02.2023
Impfdatum
14.02.2023
Beginn
15.02.2023
Tage bis Beginn
1,0
Dosis
1
Route/Site
SC / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Injection site erythema

Symptomtext

Patient received the vaccine on 14 Feb 2023, came in for follow up on 16 Feb 2023 stating that she developed large red spot at the sight the vaccine was given on the back of right upper arm. Pt states that she noticed the spot on 15 Feb 2023. Looking at the back of the right arm there is a 7cm x 7cm light red circle with a 3cm x 3cm darker red circle in the center of the lighter red circle. Dark red circle is firm to palpation..

Weitere VAERSDATA-Felder
Praegender Schweregrund
Injection site erythema
Hospital-Tage
-
Labordaten
none
Aktuelle Erkrankungen
none
Vorgeschichte
none
Andere Medikamente
none
Allergien
none
Vorherige Impfungen
-

VAERS 2273478

MERCK & CO. INC. · VARICELLA (VARIVAX) · Charge U015687

mild
Staat
NJ
Alter
28,0
Geschlecht
F
Eingang
12.05.2022
Impfdatum
11.05.2022
Beginn
11.05.2022
Tage bis Beginn
0,0
Dosis
2
Route/Site
SC / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: unbekannt
Injection site erythema Peripheral swelling

Symptomtext

Arm swelling and redness at the injection sight

Weitere VAERSDATA-Felder
Praegender Schweregrund
Injection site erythema
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
none reported
Vorgeschichte
none reported
Andere Medikamente
none reported
Allergien
sulfa drugs
Vorherige Impfungen
-

VAERS 2559884

MERCK & CO. INC. · VARICELLA (VARIVAX) · Charge U015687

gering
Staat
MI
Alter
1,0
Geschlecht
F
Eingang
14.01.2023
Impfdatum
22.12.2022
Beginn
22.12.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Extra dose administered No adverse event

Symptomtext

no additional AEs; CMA calling to report concomitant administration of PROQUAD and VARIVAX to 1 year old patient on 12/22/2022. Caller states that patient received each vaccine in different thigh. No further information provided, no additional AEs, no PQCs reported.; This spontaneous report was received from a medical assistant referring to a 1-year-old female patient. Information about medical history, concurrent conditions and concomitant therapies was not provided. On 22-DEC-2022, the patient was vaccinated with concomitant administration of varicella virus vaccine live (oka/merck)(VARIVAX) (0.5ml/once, lot # U015687, expiration date 18-MAY-2023; route was not reported)) and measles, mumps, rubella and varicella (oka-merck) virus vaccine live ((recombinant Human albumin) rHA) (PROQUAD) (0.5ml/once, lot # W024547, expiration date 31-JAN-2024, route was not reported) for prophylaxis (overdose). The patient received each vaccine in different thigh. No additional adverse event was reported.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Extra dose administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2415557

MERCK & CO. INC. · VARICELLA (VARIVAX) · Charge U015687

gering
Staat
WI
Alter
-
Geschlecht
U
Eingang
19.08.2022
Impfdatum
03.08.2022
Beginn
03.08.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Inappropriate schedule of product administration No adverse event

Symptomtext

No symptoms or adverse effects from administration of these vaccines; 4-year-old patient received PROQUAD and VARIVAX concomitantly; This spontaneous report has been received from a medical assistant referring a 4-years-old patient of unknown gender. The patient's pertinent medical history, drug allergies, previously drug reactions, concurrent conditions and concomitant medication were not reported. On 03-AUG-2022, the patient received a dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live recombinant human albumin (rHA) (PROQUAD) subcutaneous injection, at the dose of 0.5 milliliters (ml), once for prophylaxis, (lot number U031561 had been verified to be a valid number, expiration date was reported and established as 06-APR-2023) (strength, route of administration and anatomical location were not provided). And with varicella virus vaccine live (oka/merck) (VARIVAX) subcutaneous injection, at the dose of 0.5 ml for prophylaxis, (lot number U015687 had been verified to be a valid number, expiration date was reported and establised as 18-MAY-2023) (strength, route of administration and anatomical location were not provided) (drug use for unapproved schedule). Both reconstituted with sterile diluent solution for injection, at a dose of 0.7 ml (lot number T020662 had been verified to be a valid number, expiration date was reported and established as 30-DEC-2022). Patient had no symptoms or adverse effects from administration of these vaccines.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Inappropriate schedule of product administration
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
Prophylaxis
Vorgeschichte
-
Andere Medikamente
STERILE DILUENT
Allergien
-
Vorherige Impfungen
-